Church & Dwight visits NYSE, reports EPS increase
PRINCETON, N.J. — Church & Dwight celebrated an earnings per share increase of 10% to $3.75 per share by ringing the closing bell at the New York Stock Exchange Tuesday.
C&D posted 2010 sales increases of 2.7% to $2.6 billion.
“We are very proud of the business results that we accomplished in 2010,” stated James Craigie, C&D chairman and CEO. “Despite weak consumer demand and intense price competition … we were able to increase market share in 6-of-our-8 power brands in 2010 and ended the year with strong consumption in our major brands.”
Pharmavite’s GreatMind claims vetted by NAD
NEW YORK — The National Advertising Division of the Council of Better Business Bureaus on Wednesday announced that Pharmavite is able to support advertising claims for the company’s NatureMade GreatMind dietary supplement, pursuant to NAD’s ongoing monitoring of advertising for dietary supplements.
NAD, the advertising industry’s self-regulatory forum, reviewed claims that appeared in print and Internet advertising and on product packaging, pursuant to NAD’s ongoing monitoring of advertising for dietary supplements.
According to the advertiser, the product is a cognitive health supplement, based on a formulation developed and studied by Thomas Shea at the University of Massachusetts, Lowell. The formulation had been studied in subjects with early, moderate, and later-stage Alzheimer’s disease. Those subjects showed improvement on certain cognitive and dementia rating scales, and formulation was then later studied in healthy subjects using cognitive scales to evaluate the effects, NAD stated.
GreatMind contains vitamin E, folic acid, vitamin B12, N-acetyl-L-cysteine, acetyl-L-carnitine hydrochloride, and SAM-e in the same formulation as the ingredients used in the studies conducted by Dr. Shea and his colleagues, although the amount of vitamin B12 in GreatMind was increased to 12 mcg from 6 mcg. NAD noted in its decision that the first Shea study was a double-blind study, with 93 participants; the second, a six-month trial with the 38 subjects and no control; and the third, a two-week study with 43 subjects that compared treatment with the nutraceutical formulation with placebo.
Following its review of the evidence in the record, NAD concluded that the results of the Shea studies, which found statistically significant improvement in various measures of cognitive ability in those participants taking GreatMind, provided a reasonable basis for the specific claims about the supplement’s ability to improve and maintain memory and cognitive ability.
“Pharmavite believes consumers are best served when advertisers are held to the rigorous standards employed by NAD and appreciates the opportunity to participate in the self-regulatory process,” Pharmavite stated in its advertiser statement to NAD.
Prestige rides OTC crest in Q3 gains
IRVINGTON, N.Y. — Prestige Brands posted gains of 22.7% in revenue, reaching $90.6 million for its third quarter ended Dec. 31.
The company’s revenue from its five core over-the-counter brands — Chloraseptic, Clear Eyes, Compound W, Little Remedies and The Doctor’s NightGuard — increased 14% over the period. That kind of sales story is expected to improve in the coming year as Prestige assumes the reigns of the recently acquired Dramamine and Blacksmith Brands’ stable of brands — including cough-cold brands PediaCare, Luden’s and NasalCrom.
"Our strategy for growing the core OTC brands is well under way,” stated Prestige president and CEO Matthew Mannelly. “Increased investment in advertising and promotion coupled with new product introductions resulted in strong sell through during the quarter,” he said. “Consumption for Prestige’s core OTC brands, including Blacksmith Brands, grew 26.5% during the quarter."
With the addition of Dramamine, Prestige now fields nine core OTC brands, Mannelly said, representing approximately 90% of its OTC segment revenue.